05.23.19
ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, has signed a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, Abcuro has developed a new first in class antibody for autoimmunity and oncology indications.
ProBioGen will conduct the full service package from cell line development using its CHO.RiGHT expression platform over process development until GMP manufacturing. Since killing target cells is the critical mode of action of Abcuro’s antibody, ProBioGen’s antibody-dependent cellular cytotoxicity (ADCC) enhancer technology GlymaxX will be an integral part of cell line development.
“We are glad to have started our collaboration with Abcuro,” said ProBioGen’s chief executive officer Dr. Wieland Wolf. “This is yet another project that benefits not only from our proven development and manufacturing capabilities but also our proprietary technology platform for drug candidate optimization. It reflects again the continuing demand for our advanced optimization technologies.”
“Working with the right partner is a critical element in developing a compelling product candidate,” said Stefano Gullà, Abcuro’s chief executive officer. “Thus we are excited to work with ProBioGen as they have the experience, the technical expertise and a very committed team. ProBioGen is well known in the community to provide highest quality in proven timelines. Abcuro’s commitment to developing life-changing therapies for patients is a perfect match for their focus on the client’s needs.”
ProBioGen will conduct the full service package from cell line development using its CHO.RiGHT expression platform over process development until GMP manufacturing. Since killing target cells is the critical mode of action of Abcuro’s antibody, ProBioGen’s antibody-dependent cellular cytotoxicity (ADCC) enhancer technology GlymaxX will be an integral part of cell line development.
“We are glad to have started our collaboration with Abcuro,” said ProBioGen’s chief executive officer Dr. Wieland Wolf. “This is yet another project that benefits not only from our proven development and manufacturing capabilities but also our proprietary technology platform for drug candidate optimization. It reflects again the continuing demand for our advanced optimization technologies.”
“Working with the right partner is a critical element in developing a compelling product candidate,” said Stefano Gullà, Abcuro’s chief executive officer. “Thus we are excited to work with ProBioGen as they have the experience, the technical expertise and a very committed team. ProBioGen is well known in the community to provide highest quality in proven timelines. Abcuro’s commitment to developing life-changing therapies for patients is a perfect match for their focus on the client’s needs.”
